UniQure appoints 2 board members | S&P Global Market Intelligence

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Hosted EventsThe Future of Credit and Risk Management: Trends, Challenges, and Opportunities in Europe
- 03/28/2023
- CIRCL, Amsterdam
- 08:30 - 13:00 Central European Time
WebinarDemystifying Sustainability Data Management and Regulatory Reporting
- 03/21/2023
- Live, Online
- 10:00 am - 11:00 am EDT | 2:00 pm - 3:00 pm GMT
WebinarThe 2022 Top Bank & Credit Union Rankings Release - National rankings
- 03/21/2023
- Live, Online
- 2:00 pm - 2:45 pm EDT
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

UniQure appoints 2 board members

A Cloud Migration Plan for Corporations featuring Snowflake®

Investor Activism Campaigns Hit Record High in 2022

Essential IR Insights Newsletter - February 2023

Insight Weekly: US bank margins rise; smartphone shipments drop; coal miners book strong sales

13 Jun, 2018 | 20:25

UniQure appoints 2 board members

Author Armughan Khawaja
Theme Healthcare & Pharmaceuticals

Amsterdam-based gene therapy company uniQure NV appointed Robert Gut and David Meek to the board.

Gut is currently the chief medical officer for Versartis Inc. Meek has been the CEO of Ipsen SA since 2016.